TrialBritish journal of clinical pharmacology2017

Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies.

Stephen Norris et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.